Opdualag is named as an intervention in 7 current clinical trials in our Australia, Canada, USA and Israel registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Melanoma Institute Australia (3). The most-studied condition is Melanoma Stage IV.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Melanoma Stage IV | 2 |
| Cutaneous Melanoma | 2 |
| Cancer | 1 |
| Melanoma Stage III | 1 |
| Mucosal Melanoma | 1 |
| Childhood Cancer | 1 |
| Childhood Solid Tumor | 1 |
| Childhood Brain Tumor | 1 |
| Recurrent Cancer | 1 |
| Cutaneous Squamous Cell Carcinoma | 1 |
| Merkel Cell Carcinoma | 1 |
| Stage II Melanoma | 1 |
| Renal Cell Carcinoma, Clear Cell | 1 |
| Lead sponsor | Trials |
|---|---|
| Melanoma Institute Australia | 3 |
| Krystal Biotech, Inc | 1 |
| University Health Network, Toronto | 1 |
| Australian & New Zealand Children's Haematology/Oncology Group | 1 |
| M.D. Anderson Cancer Center | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Australia | 4 | 3 |
| Clinical trials in Canada | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Israel | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our Australia, Canada, USA and Israel registers name Opdualag (also registered as BMS-986213) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 7 trials are recruiting: 3 with sites in Australia, 2 with sites in Canada and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Melanoma Institute Australia (3), Krystal Biotech, Inc (1), University Health Network, Toronto (1) and Australian & New Zealand Children's Haematology/Oncology Group (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Opdualag works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Opdualag works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Opdualag (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.